Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies
- PMID: 182897
- PMCID: PMC2190413
- DOI: 10.1084/jem.144.3.739
Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies
Abstract
Passive transfer of experimental autoimmune myasthenia gravis (EAMG) was achieved using the gamma globulin fraction and purified IgG from sera of rats immunized with Electrophus electricus (eel) acetylcholine receptor (AChR). This demonstrates the critical role of anti-AChR antibodies in impairing neuromuscular transmission in EAMG. Passive transfer of anti-AChR antibodies from rats with chronic EAMG induced signs of the acute phase of EAMG in normal recipient rats, including invasion of the motor end-plate region by mononuclear inflammatory cells. Clinical, eletrophysiological, histological, and biochemical signs of acute EAMG were observed by 24 h after antibody transfer. Recipient rats developed profound weakness and fatigability, and the posture characteristic of EAMG. Striking weight loss was attributable to dehydration. Recipient rats showed large decreases in amplitude of muscle responses to motor nerve stimulation, and repetitive nerve stimulation induced characteristic decrementing responses. End-plate potentials were not detectable in many muscle fibers, and the amplitudes of miniature end-plate potentials were reduced in the others. Passively transferred EAMG more severely affected the forearm muscles than diaphragm muscles, though neuromuscular transmission was impaired and curare sensitivity was increased in both muscles. Some AChR extracted from the muscles of rats with passively transferred EAMG was found to be complexed with antibody, and the total yield of AChR per rat was decreased. The quantitative decrease in AChR approximately paralleled in time the course of clinical and electrophysiological signs. The amount of AChR increased to normal levels and beyond at the time neuromuscular transmission was improving. The excess of AChR extractable from muscle as the serum antibody level decreased probably represented extrajunctional receptors formed in response to functional denervation caused by phagocytosis of the postsynaptic membrane by macrophages. The amount of antibody required to passively transfer EAMG was less than required to bind all AChR molecules in a rat's musculature. The effectiveness of samll amounts of antibody was probably amplified by the activation of complement and by the destruction of large areas of postsynaptic membrane by phagocytic cells. A self-sustaining autoimmune response to AChR was not provoked in animals with passively transferred EAMG.
Similar articles
-
Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis.J Exp Med. 1978 Apr 1;147(4):973-83. doi: 10.1084/jem.147.4.973. J Exp Med. 1978. PMID: 206648 Free PMC article.
-
Pathological mechanisms in experimental autoimmune myasthenia gravis. I. Immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental automimmune myasthenia gravis.J Exp Med. 1976 Sep 1;144(3):726-38. doi: 10.1084/jem.144.3.726. J Exp Med. 1976. PMID: 182896 Free PMC article.
-
Passively transferred experimental autoimmune myasthenia gravis. Sequential and quantitative study of the motor end-plate fine structure and ultrastructural localization of immune complexes (IgG and C3), and of the acetylcholine receptor.Neurology. 1979 Feb;29(2):179-88. doi: 10.1212/wnl.29.2.179. Neurology. 1979. PMID: 571062
-
Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?Arch Immunol Ther Exp (Warsz). 2012 Feb;60(1):19-30. doi: 10.1007/s00005-011-0158-6. Epub 2011 Dec 8. Arch Immunol Ther Exp (Warsz). 2012. PMID: 22159475 Review.
-
AChR-specific immunosuppressive therapy of myasthenia gravis.Biochem Pharmacol. 2015 Oct 15;97(4):609-619. doi: 10.1016/j.bcp.2015.07.011. Epub 2015 Jul 26. Biochem Pharmacol. 2015. PMID: 26215875 Review.
Cited by
-
Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis.J Exp Med. 1978 Apr 1;147(4):973-83. doi: 10.1084/jem.147.4.973. J Exp Med. 1978. PMID: 206648 Free PMC article.
-
Immunopathologic events at the endplate in myasthenia gravis.Springer Semin Immunopathol. 1985;8(3):177-96. doi: 10.1007/BF00197295. Springer Semin Immunopathol. 1985. PMID: 2413561 Review. No abstract available.
-
Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.J Neurol. 2021 May;268(5):1643-1664. doi: 10.1007/s00415-019-09498-4. Epub 2019 Sep 3. J Neurol. 2021. PMID: 31482201 Review.
-
Experimental autoimmune myasthenia gravis.J Neurol Neurosurg Psychiatry. 1980 Jul;43(7):568-76. doi: 10.1136/jnnp.43.7.568. J Neurol Neurosurg Psychiatry. 1980. PMID: 6249892 Free PMC article.
-
Autoreactive T Cells from Patients with Myasthenia Gravis Are Characterized by Elevated IL-17, IFN-γ, and GM-CSF and Diminished IL-10 Production.J Immunol. 2016 Mar 1;196(5):2075-84. doi: 10.4049/jimmunol.1501339. Epub 2016 Jan 29. J Immunol. 2016. PMID: 26826242 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources